Alan Cash to Present Oxaloacetate CFS Clinical Trial Results at 2025 IACFS/ME Virtual Conference

Alan Cash, Chief Science Officer of Oxaloacetate CFS, will present the latest Oxaloacetate CFS clinical trial data at the International Association of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME) 2025 Virtual Research and Medical Conference on October 23, 2025, at 9:05 AM Eastern Time.

Cash's presentation, “Oxaloacetate Clinical Trial Results for ME/CFS and Long COVID Patients”, will highlight data from randomized controlled trials showing the ability of Oxaloacetate CFS to significantly reduce fatigue and improve cognitive function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID patients.

The IACFS/ME Virtual Research and Medical Conference is the premier international meeting dedicated to the biomedical, clinical, and epidemiological aspects of ME/CFS, attracting leading scientists, clinicians, and patient advocates from around the world.

For more information about the conference, visit https://www.iacfsme.org.